Tebentafusp Regimen Versus Investigator's Choice in Previously Treated Advanced Melanoma (TEBE-AM)
Trial details
- Registry ID
- NCT05549297
- Drugs studied
- Investigators Choice, Tebentafusp, Tebentafusp with Pembrolizumab
TrialRedline tracks 3 clinical trials sponsored by Immunocore Ltd: 2 Phase 3, 1 Phase 2.
Company identity has not yet been verified
| Trial | Drugs studied | Status | Primary completion |
|---|---|---|---|
| Tebentafusp Regimen Versus Investigator's Choice in Previously Treated Advanced Melanoma (TEBE-AM)NCT05549297 | Investigators Choice, Tebentafusp, Tebentafusp with Pembrolizumab | Recruiting | 2028-03Estimated |
| IMC-F106C Regimen Versus Nivolumab Regimens in Previously Untreated Advanced Melanoma (PRISM-MEL-301)NCT06112314 | Brenetafusp, Nivolumab, Nivolumab + Relatlimab | Recruiting | 2027-10-16Estimated |
| Trial | Drugs studied | Status | Primary completion |
|---|---|---|---|
| Safety and Efficacy of IMCgp100 Versus Investigator Choice in Advanced Uveal MelanomaNCT03070392 | Dacarbazine, IMCgp100, Ipilimumab, Pembrolizumab | Completed | 2020-10-13Actual |
Names as written in the registry records.
NCT03070392 · Immunocore Ltd
Text changed; whether the study measures changed has not been verified. Saved text may be shortened.
Before: Measure: Efficacy: Overall Survival Description: Overall survival is defined as the time from randomization to date of death due to any cause. Time frame: From randomization to the data cut off date of 13-Oct-2020; median follow-up duration was 14.1 months.. After: Measure: Overall Survival Description: Overall survival is defined as the time from randomization to date of death due to any cause. Time frame: From randomization to the data cut off date of 13-Oct-2020; median follow-up duration was 14.1 months..
NCT03070392 · Immunocore Ltd
Before: Active not recruiting. After: Completed.